Boston Scientific jumps after Q1 revenue beat and upbeat EPS outlook
Boston Scientific shares rose after reporting Q1 2026 revenue of $5.203 billion (+11.6% reported) and adjusted EPS of $0.80. The company’s Q2 EPS outlook of $0.82–$0.84 and full-year EPS outlook of $3.34–$3.41 reinforced expectations for continued growth.
1. What’s moving the stock today
Boston Scientific (BSX) is trading higher after releasing first-quarter 2026 results on April 22, 2026, showing faster-than-expected top-line growth and an outlook that kept near-term earnings momentum intact. The company posted net sales of $5.203 billion, up 11.6% reported (9.4% operational/organic), and delivered adjusted EPS of $0.80, matching the top end of its guidance range.
2. Key numbers investors are reacting to
Q1 GAAP EPS was $0.90 versus $0.45 a year earlier, while adjusted EPS increased to $0.80 from $0.75. Revenue strength was broad-based, with Cardiovascular net sales up 13.5% reported (11.2% operational/organic) and MedSurg up 7.8% reported (5.7% operational/organic), supporting the view that procedure volumes and category leadership are translating into durable growth.
3. Guidance and next catalyst
For the June quarter, Boston Scientific expects EPS of $0.82 to $0.84, and it guided full-year EPS to $3.34 to $3.41. Management is scheduled to discuss the quarter on an 8:00 a.m. ET conference call, which can further move the stock if investors get incremental detail on demand trends, pipeline execution, and the cadence of growth through 2026.